PGZ.F Healius Limited

Healthcare Biotechnology Frankfurt Exchange
0.3320 EUR
Close of Nov 13, 2026
0.1700 0.6150
Market cap
EUR 241M
P/E
-
P/B
2.12x
ROE
-242.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is PGZ.F undervalued?

Graham number

The Graham number of Healius Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Healius Limited fundamental analysis

No fundamental analysis for Healius Limited yet.

Healius Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Healius Limited

Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab Dermatopathology, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care L…

Full company profile